Risk Profiling of Cancer Treatment-Related Cardiovascular Disorders in Breast Cancer Patients Who Received Adjuvant Chemotherapy With Trastuzumab
Open Access
- 10 April 2020
- journal article
- Published by Japanese Circulation Society in Circulation Reports
- Vol. 2 (4), 235-242
- https://doi.org/10.1253/circrep.cr-19-0119
Abstract
Background:The prognosis of cancer survivors has dramatically improved, but effective strategies for cancer treatment-related cardiovascular disorders (CTRCD) remain to be elucidated in the emerging field of cardio-oncology. In this study, we investigated risk factors for CTRCD in breast cancer patients treated with trastuzumab. Methods and Results:We performed a retrospective analysis of 141 consecutive women who received adjuvant trastuzumab, and underwent baseline (BL) and follow-up (FU) echocardiography at Juntendo University between April 2010 and December 2016. The major concomitant treatment was anthracyclines in 94% and radiotherapy in 53%. During the median treatment period of 11 months, there were 22 (15.6%) cardiology consultations, 3 (2.1%) treatment interruptions with irreversible CTRCD, and no deaths. Left ventricular ejection fraction (LVEF) was decreased from a median 67.5% (BL) to 63.4% (FU; PFUFUConclusions:Adjuvant trastuzumab for early-stage breast cancer was associated with reduced LVEF; and CVRF were an independent predictor for CTRCD. The concomitant effect of anthracyclines should not be underestimated, even at lower doses.Keywords
This publication has 48 references indexed in Scilit:
- Adjuvant Trastuzumab in HER2-Positive Breast CancerThe New England Journal of Medicine, 2011
- Lack of Uniformity in Cardiac Assessment during Trastuzumab TherapyThe Breast Journal, 2011
- Safety of adjuvant trastuzumab for HER-2-overexpressing elderly breast cancer patients: a multicenter cohort studyBreast Cancer, 2011
- The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology SocietyProgress in Cardiovascular Diseases, 2010
- Cardiotoxicity of anticancer treatments: what the cardiologist needs to knowNature Reviews Cardiology, 2010
- Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic TherapyJournal of the American College of Cardiology, 2010
- Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancerInternational Journal of Clinical Oncology, 2009
- Cardiac Dysfunction in the Trastuzumab Clinical Trials ExperienceJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2The New England Journal of Medicine, 2001
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989